GlassScriptPhysician profile
Meredith C Hitch
NPI 1134269848
$5,842.86
in general payments reported to CMS, 2019-2025
34 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $779 · 2020: $221 · 2021: $719 · 2022: $1,000 · 2023: $476 · 2024: $2,648.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,412 · Food and Beverage: $712.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,412.00 |
| Food and Beverage | $711.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Pharmaceuticals, INC. | $2,412.00 | 2024 | Dupixent |
| Abbvie INC. | $693.57 | 2019-2021 | |
| Qol Medical, LLC | $553.18 | 2019-2024 | Sucraid |
| Genzyme Corporation | $235.09 | 2022-2024 | |
| Regeneron Healthcare Solutions, INC. | $223.06 | 2022-2023 | Dupixent |
| Jazz Pharmaceuticals INC. | $214.51 | 2020-2022 | |
| Ucb, INC. | $173.94 | 2020-2022 | |
| Insulet Corporation | $145.94 | 2022-2023 | Omnipod |
| Dexcom, INC. | $145.16 | 2021-2024 | Dexcom G6 Transmitter |
| Eisai INC. | $138.39 | 2020-2022 | |
| Cumberland Pharmaceuticals, INC. | $125.79 | 2019-2023 | Kristalose |
| Xeris Pharmaceuticals, INC. | $99.06 | 2020-2022 | |
| Sunovion Pharmaceuticals INC. | $82.05 | 2020-2021 | |
| Nestle Healthcare Nutrition INC. | $75.46 | 2023 | |
| Ascendis Pharma Endocrinology INC | $47.24 | 2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zogenix INC. | $47.15 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $43.29 | 2022-2023 | Gattex |
| Greenwich Biosciences, INC. | $43.23 | 2020 | |
| Aquestive Therapeutics, INC. | $40.79 | 2021-2022 | |
| Shire North American Group INC | $35.51 | 2019 | |
| Novo Nordisk INC | $32.55 | 2020-2021 | |
| Travere Therapeutics, INC. | $27.53 | 2019 | |
| Corium, LLC | $24.88 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $24.88 | 2022 | |
| Amgen INC. | $21.03 | 2022 | |
| Sobi, INC | $18.33 | 2020 | |
| Eton Pharmaceuticals, INC. | $18.00 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $17.56 | 2022 | |
| Concordia Pharmaceuticals INC. | $16.20 | 2019 | |
| Arbor Pharmaceuticals, INC. | $15.81 | 2021 | |
| Sarepta Therapeutics, INC. | $14.86 | 2021 | |
| Daiichi Sankyo INC. | $14.18 | 2022 | |
| Aprecia Pharmaceuticals, LLC | $11.56 | 2020 | |
| Supernus Pharmaceuticals, INC. | $11.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meredith Hitch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.